Journal of Clinical Pathways最新文献

Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment 范式转变：人工智能在癌症治疗中的影响

Journal of Clinical Pathways Pub Date : 2024-06-01 DOI: 10.25270/jcp.2024.05.03

Stephen Speicher, Will Shapiro, Taylor Dias-Foundas

引用次数: 0

PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing 泌尿外科诊所中使用新一代雄激素受体抑制剂治疗的非转移性阉割耐药前列腺癌患者的 PSA 结果和临床监测（无论是否进行诊室配药

Journal of Clinical Pathways Pub Date : 2024-06-01 DOI: 10.25270/jcp.2024.05.01

Sabree C Burbage, Dexter Waters, C. Rossi, F. Kinkead, Erik Muser, L. Ellis, Patrick Lefebvre, D. Pilon

{"title":"PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing","authors":"Sabree C Burbage, Dexter Waters, C. Rossi, F. Kinkead, Erik Muser, L. Ellis, Patrick Lefebvre, D. Pilon","doi":"10.25270/jcp.2024.05.01","DOIUrl":"https://doi.org/10.25270/jcp.2024.05.01","url":null,"abstract":"This retrospective study used electronic medical record data from community-based urology practices in the US (February 1, 2017, to September 17, 2021) to describe prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services. Patients who were prescribed apalutamide, darolutamide, or enzalutamide were classified in IOD+ (IOD access + fill), IOD– (IOD access + no fill), or non-IOD cohorts (no IOD access). Outcomes were described by cohort from 14 days following initial prescription to the earliest of initiation of a new ARI or advanced prostate cancer medication, end of clinical activity, or end of data availability. In total, 3300 patients were included (IOD+: n = 615; IOD–: n = 2474; non-IOD: n = 211). PSA response defined as a decline ≥50% from the baseline PSA value (PSA50) achieved by 6 and 12 months was observed in 80.0% and 83.8% of patients in the IOD+ cohort, 63.8% and 72.3% in the IOD– cohort, and 62.5% and 69.1% in the non-IOD cohort. Patients in the IOD+ cohort underwent fewer bone scans, computerized tomography, and next-generation imaging than IOD– and non-IOD cohorts and also had longer time from treatment initiation to first follow-up imaging. IOD services may better support comprehensive disease management for patients with nmCRPC receiving next-generation ARIs and may be associated with better long-term clinical outcomes.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141275459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bringing Value to Health Care 为医疗保健带来价值

Journal of Clinical Pathways Pub Date : 2024-06-01 DOI: 10.25270/jcp.2024.05.02

Andrew L Pecora, Lili Brillstein, M. Albitar, Nasim Asfar, Joel Brill, Jeffrey R. Curtis, Andrew von Eschenbach, Deborah Goss, Andre Goy, Max Holfert, Andrew Ip, Allen Karp, Mark Lutes, Steven Madreperla, Patrick A. Roth, Miruna Sasu, Robert Shelley, Robin L. Smith, Nina Tandon, Dan Varga, Richard Winters

引用次数: 0

Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results 造血干细胞移植受者的患者报告结果：设计、实施和试点结果

Journal of Clinical Pathways Pub Date : 2024-04-01 DOI: 10.25270/jcp.2024.03.02

C. Hayes, A. V. Van Citters, Wenyan Zhao, Kate L. Caldon, Charlotte M. Coughenour, T. Tosteson, Anna N. A. Tosteson, Kenneth R. Meehan

{"title":"Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results","authors":"C. Hayes, A. V. Van Citters, Wenyan Zhao, Kate L. Caldon, Charlotte M. Coughenour, T. Tosteson, Anna N. A. Tosteson, Kenneth R. Meehan","doi":"10.25270/jcp.2024.03.02","DOIUrl":"https://doi.org/10.25270/jcp.2024.03.02","url":null,"abstract":"Background: Patient-reported outcome measures (PROMs) offer a collaborative opportunity between the patient and the care team to improve the quality of care. Objectives: To define PROMs in patients receiving hematopoietic stem cell transplant (HSCT), a pre-visit questionnaire (PVQ) was developed, which included a single agenda-setting question, the PROMIS-29 survey, and the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT). Study Design: Patients completed the PVQ 1 month prior to transplant (baseline) and at 1, 3, 6, and 12 months following transplant. Results: Sixty-five patients (n = 27 allogenic; n = 38 autologous) participated. Survey completion rates were 95% at 1 month post-transplant, 74% at 6 months, and 65% at one year. One month following transplant, patients’ fatigue (P < .001) increased, while physical (P < .001) and social (P < .001) functions decreased. Each returned to baseline at 3 months (P < .001). Fatigue was more pronounced in allogeneic recipients (P = .017) and autologous recipients recovered physical function much sooner (P = .021). Conclusions: This study confirms the feasibility of capturing PROMs longitudinally in patients receiving HSCT and demonstrates significant changes in fatigue and physical and social functioning following transplant.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140356990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive Genomic Testing: Tissue Stewardship and Best Practices 综合基因组测试：组织管理与最佳实践

Journal of Clinical Pathways Pub Date : 2024-04-01 DOI: 10.25270/jcp.2024.03.01

R. Previs, Maureen E. Cooper, Kyle C. Strickland, Heidi Ko, Michelle F. Green, F. Koohestani, S. Hastings, Zachary D. Wallen, S. Pabla, Jeffrey M. Conroy, M. Nesline, Shengle Zhang, Durga Prasad Dash, Brian J. Caveney, Marcia Eisenberg, Eric A Severson, Shakti H. Ramkissoon

引用次数: 0

The Key Factors Driving Low Participation in the Enhancing Oncology Model 导致 "加强肿瘤治疗模式 "参与率低的关键因素

Journal of Clinical Pathways Pub Date : 2024-02-01 DOI: 10.25270/jcp.2024.01.01

Theresa Dreyer

{"title":"The Key Factors Driving Low Participation in the Enhancing Oncology Model","authors":"Theresa Dreyer","doi":"10.25270/jcp.2024.01.01","DOIUrl":"https://doi.org/10.25270/jcp.2024.01.01","url":null,"abstract":"This study investigates the challenges leading to a substantial decline in participation among academic oncology practices within the Enhancing Oncology Model (EOM), introduced as a successor to the Oncology Care Model (OCM) by the CMS Innovation Center. Analyzing the withdrawal of 14 practices from the EOM, previously part of the OCM Collaborative, three primary factors are identified: immediate downside risk in a context of narrow provider margins, inadequate risk adjustment failing to appropriately account for drug costs, and onerous reporting burdens for extensive clinical data. Under the EOM, immediate downside risk for seven specified cancers diverged significantly from the OCM’s upside-only risk structure, posing financial challenges for practices. Inadequate risk adjustment, particularly the omission of crucial clinical data, raised concerns about the model’s focus on drug costs without considering essential patient-specific variables. The study also highlights the burden of reporting requirements, exacerbated by reduced enhanced services payments, impacting practices financially. To address these challenges and encourage EOM participation, policy options are proposed. These include reconsidering financial risk levels, refining target price methodology to incorporate clinical data, and reducing reporting burdens by aligning data requirements with EOM financial and quality methodologies. These adjustments aim to strengthen the EOM, fostering more accurate performance measurement and incentivizing high-quality patient care delivery in oncology practices.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Multidisciplinary Team Processes in Lung Cancer Care: A Self-Assessment Toolkit and Best Practices 加强肺癌护理中的多学科团队流程：自我评估工具包和最佳做法

Journal of Clinical Pathways Pub Date : 2024-02-01 DOI: 10.25270/jcp.2024.01.02

Poka Cui, Peter Blanshard, María Teresa Campos-Partera, A. Moucquot, S. H. R. Naqvi, D. Dellamonica, Heather Moses

{"title":"Enhancing Multidisciplinary Team Processes in Lung Cancer Care: A Self-Assessment Toolkit and Best Practices","authors":"Poka Cui, Peter Blanshard, María Teresa Campos-Partera, A. Moucquot, S. H. R. Naqvi, D. Dellamonica, Heather Moses","doi":"10.25270/jcp.2024.01.02","DOIUrl":"https://doi.org/10.25270/jcp.2024.01.02","url":null,"abstract":"Multidisciplinary teams (MDTs) play a pivotal role in the comprehensive management of cancer. MDT meetings (MDTMs) bring together specialized experts across the entire patient care spectrum, convening regularly to discuss patient cases, select optimal diagnostic strategies, and determine the most appropriate treatment modalities. By fostering cross-disciplinary interaction, MDTs aim to enhance patient outcomes and elevate the collective proficiency within a health care institution, promoting knowledge dissemination and ensuring health care practitioners remain abreast of the latest clinical insights. This study’s methods comprised an extensive review of existing literature coupled with interviews involving lung cancer MDTs from 24 medical centers across Europe and Canada. The research focused on elucidating dynamics and variations observed among lung cancer MDTs, outlining an optimal MDT process, identifying variances in the study sample, and introducing a comprehensive self-assessment toolkit for continuous evaluation and improvement. The report discusses how these results should be used to self-optimize hospital MDTs, promote standardization, and encourage increased cross-hospital best practices sharing. With this, MDTs will be better positioned to deliver on the key goal of improved patient outcomes while promoting equality of access to health care.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Social Determinants of Health Beyond Race on Survival in Metastatic Prostate Cancer: A Systematic Literature Review 种族之外的健康社会决定因素对转移性前列腺癌患者生存期的影响：系统性文献综述

Journal of Clinical Pathways Pub Date : 2023-12-01 DOI: 10.25270/jcp.2023.11.01

S. Freedland, Imtiaz Samjoo, Emily Rosta, A. Lansing, Alexandra Hall, Manvir Rai, A. Niyazov, J. Nazari, B. Arondekar

引用次数: 0

Clinical and Economic Impact of Implementing HealthPathways at a Musculoskeletal Radiology Department 在肌肉骨骼放射科实施健康之路的临床和经济影响

Journal of Clinical Pathways Pub Date : 2023-12-01 DOI: 10.25270/jcp.2023.11.02

Simon Davies, Kathleen Lyons, Kausik Mukherjee, Ramakrishna Kishore, Khurram Hashmi, Maria Dyban, Anna Kuczynska

引用次数: 0